-
LifeNet Health launches minimally invasive bone graft system
Virginia Beach, Va.-based LifeNet Health launched the ViviGen minimally invasive surgery delivery system. -
What surgeons are saying about regenerative medicine in 2021
Regenerative medicine remains a hot topic among spine and orthopedic surgeons. From stem cell treatments to bone grafts, biologic technology is growing, and many surgeons are optimistic. -
Regenerative medicine market to hit $172B+ by 2030
The regenerative medicine market is expected to hit $172.15 billion by 2030, according to market research from Next Move Strategy Consulting. -
7 key updates in biologics
Here are seven updates in orthopedic biologics in the last 90 days: -
Regenerative treatment clinic opens in Hawaii
A new clinic in Honolulu focuses on non-surgical treatments for orthopedic injuries. -
Bioventus lines up another $500M acquisition — 5 details
One month after Bioventus announced its plan to acquire spine devicemaker Misonix in a $518 million deal, the orthobiologics company is lining up a reported $500 million purchase of Israeli medtech company Cartiheal. -
OrthoRTI extends clinical hold of biologics drug
Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release. -
Stem Cell Institute of America sued, accused of falsely marketing treatments for ortho pain
The co-founders of the Stem Cell Institute of America are being sued, accused of marketing stem cell therapy to seniors by falsely claiming that it is an effective treatment for orthopedic conditions such as arthritis and joint pain. -
Bioventus to acquire spine company for $518M
Bioventus has entered an agreement to acquire Misonix for $518 million in a cash-and-stock transaction. -
Orthofix launches new allograft line for spine surgery
Implant manufacturer Orthofix has launched FiberFUSE Strip, a demineralized bone graft intended to promote bone growth after spine surgery, in the U.S. -
Ortho RTI updates on clinical hold for drug trial
Ortho Regenerative Technologies has submitted requested data related to its Ortho-R drug to the FDA after the company paused its clinical trial. -
Vivex Biologics launches bone graft substitutes
Vivex Biologics launched its Via Mend synthetic bone fillers, a line of bone graft substitutes, the company announced July 15. -
Bioventus in 2021: 5 updates to know
Since launching its initial public offering in February, orthobiologics company Bioventus marked several notable achievements, including a multimillion-dollar acquisition. -
Bioventus launches flowable bone graft substitute
Durham, N.C.-based Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable, the company said July 13. -
RTI Surgical, Exactech strike biologic partnership
Orthopedic device company RTI Surgical partnered with Exactech to develop and supply biologic bone grafts. -
Hospital for Special Surgery surgeon receives $50K grant for orthobiologics research
Orthopedic surgeon Scott Rodeo, MD, of New York City-based Hospital for Special Surgery received a $50,000 grant from the Orthopaedic Research and Education Foundation to study an injectable knee biologic. -
More lawsuits filed against spine biologics company after patients sickened with tuberculosis
Lawsuits on behalf of a Florida woman and a Delaware man were filed against Aziyo Biologics after they received a tainted FiberCel implant. -
Celularity, Arthrex agree to distribute orthopedic biomaterials
Orthopedic device company Arthrex struck a deal with Celularity to distribute biomaterial products for orthopedic surgery, according to a July 1 news release. -
91 patients treated for TB after spine surgery with infected allograft
The number of patients treated for tuberculosis after undergoing spine surgery with FiberCel, a bone matrix allograft, is growing. -
Ortho RTI adds to board of directors
Ortho Regenerative Technologies named Howard Walthall and Tim Cunningham to its board of directors, the company said June 15.
Page 9 of 34